DOI: https://doi.org/10.15587/2313-8416.2015.36499

Факторы прогноза при первичных миелодиспластических синдромах у лиц молодого и среднего возраста

Наталья Николаевна Климкович, Ольга Владимировна Красько, Татьяна Ивановна Козарезова

Аннотация


Проведен анализ прогностической значимости клинико-лабораторных параметров при первичных миелодиспластических синдромах у лиц возрастной группы 18–60 лет. Установлено, что значения экспрессии CD95 клетками КМ ≤40 % и FLT3≥60 % можно рассматривать как прогностические маркеры прогрессирования первичных миелодиспластических синдромов и временной момент обязательного старта специфической терапии


Ключевые слова


миелодиспластические синдромы; прогноз; экспрессия CD95 и FLT3

Полный текст:

PDF

Литература


Kosmider, O., Gelsi-Boyer, V., Cheok, M. et al. (2009). TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood, 114 (15), 3285–3291. doi: 10.1182/blood-2009-04-215814

Kjeldsen, L., Dybedal, I., Hellström-Lindberg, E. et al. (2010). Guidelines for the diagnosis and treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Nordic MDS Group. MDS Guideline Programme, 5, 4th update, 43.

Malcovati, L., Porta, M. G., Pascutto, C. et al. (2005). Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23 (30), 7594–7603. doi: 10.1200/jco.2005.01.7038

Malcovati, L., Germing, U., Kuendgen, A. et al. (2008). Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 25 (23), 3503–3510 doi: 10.1200/jco.2006.08.5696

Weinberg, O. K., Seetharam, M., Ren, L. et al. (2009). Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood, 113 (9), 1906–1908. doi: 10.1182/blood-2008-10-182782

Cazzola, M. (2011). Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematology, 96 (3), 349–352. doi: 10.3324/haematol.2010.030023

Alessandrino, E. P., Della Porta, M. G., Bacigalupo, A. et al. (2008). WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 112 (3), 895–902. doi: 10.1182/blood-2008-03-143735

Greenberg, P., Cox, C., LeBeau, M. M. et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89 (6), 2079–2088.

Greenberg, P. L., Tuechler, H., Schanz, J. et al. (2012). Revised International prognostic scoring system for myelodysplastic syndromes. Blood, 120 (12), 2454–2465. doi: 10.1182/blood-2012-03-420489

Therneau, T. (2014). A Package for Survival Analysis in S. R package version 2.37-7. Available at: http://CRAN.R-project.org/package=survival (Last accessed: 15-09-2014).

R: A language and environment for statistical computing. R Foundation for Statistical Computing/R Core Team (2013). Vienna, Austria. Available at: http://www.R-project.org/

Brunning, R. D., Orazi, A., Germing, U. et al.; Swerdlow, S. H., Campo, E., Harris, N. L. et al. (Eds.) (2008). Myelodysplastic syndromes/neoplasms, overview. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 88–93.


Пристатейная библиография ГОСТ


1. Kosmider, O. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes [Text] / O. Kosmider, V. Gelsi-Boyer, M. Cheok et al. // Blood. – 2009. – Vol. 114, Issue 15. – P. 3285–3291. doi: 10.1182/blood-2009-04-215814 

2. Kjeldsen, L. Guidelines for the diagnosis and treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Nordic MDS Group [Text] / L. Kjeldsen, I. Dybedal, E. Hellström-Lindberg et al. // MDS Guideline Programme. – 2010. – Issue 5, 4th update. – P. 43.

3. Malcovati, L. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making [Text] / L. Malcovati, M. G. Porta, C. Pascutto et al. // Journal of Clinical Oncology. – 2005. – Vol. 23, Issue 30. – P. 7594–7603. doi: 10.1200/jco.2005.01.7038 

4. Malcovati, L. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes [Text] / L. Malcovati, U. Germing, A. Kuendgen et al. // Journal of Clinical Oncology. – 2008. – Vol. 25, Issue 23. – P. 3503–3510. doi: 10.1200/jco.2006.08.5696 

5. Weinberg, O. K. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system [Text] / O. K. Weinberg, M. Seetharam, L. Ren et al. // Blood. – 2009. – Vol. 113, Issue 9. – P. 1906–1908. doi: 10.1182/blood-2008-10-182782 

6. Cazzola, M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms [Text] / M. Cazzola // Haematologica. – 2011. – Vol. 96, Issue 3. – P. 349–352. doi: 10.3324/haematol.2010.030023 

7. Alessandrino, E. P. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) [Text] / E. P. Alessandrino, M. G. Della Porta, A. Bacigalupo et al. // Blood. – 2008. – Vol. 112, Issue 3. – P. 895–902. doi: 10.1182/blood-2008-03-143735 

8. Greenberg, P. International scoring system for evaluating prognosis in myelodysplastic syndromes [Text] / P. Greenberg, C. Cox, M. M. LeBeau et al. // Blood. – 1997. – Vol. 89. – P. 2079–2088.

9. Greenberg, P. L. Revised International prognostic scoring system for myelodysplastic syndromes [Text] / P. L. Greenberg, H. Tuechler, J. Schanz et al. // Blood. – 2012. – Vol. 120, Issue 12. – P. 2454–2465. . doi: 10.1182/blood-2012-03-420489

10. Therneau, T. Survival Analysis. R package version 2.37-7 [Electronic resource] / T. Therneau. – Available at: http://cran.r-project.org/web/packages/survival/citation.html (Last accessed: 15-09-2014).

11. R: A language and environment for statistical computing. R Foundation for Statistical Computing/R Core Team [Electronic resource] // Vienna, Austria, 2013. – Available at: http://www.R-project.org/

12. Brunning, R. D. Myelodysplastic syndromes/neoplasms, overview [Text] / R. D. Brunning, A. Orazi, U. Germing et al.; S. H. Swerdlow, E. Campo, N. L. Harris et al. (Eds.) // WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues . – 2008. – Vol. 2. – P. 87–104.







Copyright (c) 2015 Наталья Николаевна Климкович, Ольга Владимировна Красько, Татьяна Ивановна Козарезова

Creative Commons License
Эта работа лицензирована Creative Commons Attribution 4.0 International License.

ISSN 2313-8416 (Online), ISSN 2313-6286 (Print)